1910's CANDID-CNS™ AI model has been published in the Journal of Chemical Information and Modeling (JCIM), a journal of the American Chemical Society. CANDID-CNS™ is the new state-of-the-art AI model ...
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- 1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced that its CANDID-CNS (TM) AI model has been ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced that its CANDID-CNS™ AI model has been published in the Journal of Chemical Information and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback